Advanced Medical Solutions Group Full Year 2023 Earnings: EPS Misses Expectations
Advanced Medical Solutions Group (LON:AMS) Full Year 2023 Results
Key Financial Results
Revenue: UK£126.2m (up 1.5% from FY 2022).
Net income: UK£15.9m (down 22% from FY 2022).
Profit margin: 13% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses.
EPS: UK£0.074 (down from UK£0.094 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Advanced Medical Solutions Group EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.2%.
The primary driver behind last 12 months revenue was the Surgical segment contributing a total revenue of UK£79.1m (63% of total revenue). The largest operating expense was General & Administrative costs, amounting to UK£50.7m (93% of total expenses). Explore how AMS's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in the United Kingdom.
Performance of the British Medical Equipment industry.
The company's shares are down 6.0% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Advanced Medical Solutions Group's balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
